4D pharma plc, of Leeds, U.K., appointed Axel Glasmacher nonexecutive chair of its board.
Highlight Therapeutics SL, formerly known as Bioncotech Therapeutics, of Madrid, Spain, appointed Carlos Paya executive chair. It also named Ralph R. Weichselbaum, Antoni Ribas and Michael Doherty to its scientific advisory board.
Hoth Therapeutics Inc., of New York, appointed Graig Springer and Wayne Linsley to its board.
Magenta Therapeutics Inc., of Cambridge, Mass., appointed John Davis Jr. head of research and development and chief medical officer.
Olix Pharmaceuticals Inc., of Suwon, Republic of Korea, appointed Gordon Jiang, Aaron Hakim and Yury V. Popov to its scientific advisory board.
Orexo AB, of Uppsala, Sweden, appointed James Noble chair of its board. It also elected Charlotte Hansson to the board.
Oryzon Genomics SA, of Madrid, Spain, appointed Vanessa Almendro Navarro to its board as lead director and member of the remuneration and nomination committee.
PTC Therapeutics Inc., of South Plainfield, N.J., appointed Matthew Klein chief development officer and Eric Pauwels chief business officer.
Sangamo Therapeutics Inc., of Brisbane, Calif., appointed Mark McClung executive vice president and chief business officer.